Early clinical data raise the bar for hemophilia gene therapies
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In most liver-directed clinical trials, human subjects with a history of immune response to protein replacement therapy or null mutations were excluded from these studies [127, 128].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [128]
Citations
Cites
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
Nathwani, A. C., Reiss, U. M., Tuddenham, E. G. D., Rosales, C., Chowdary, P., McIntosh, J., Della Peruta, M., Lheriteau, E., Patel, N., Raj, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407309 · Cited by 1,273
Factor VIII–Mimetic Function of Humanized Bispecific Antibody in Hemophilia A
Shima, M., Hanabusa, H., Taki, M., Matsushita, T., Sato, T., Fukutake, K., Fukazawa, N., Yoneyama, K., Yoshida, H., & Nogami, K. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1511769 · Cited by 478
Moran, N. (2012) · Nature Biotechnology · doi:10.1038/nbt1212-1153 · Cited by 26
Biogen and UPenn join forces to commercialize gene therapies
Sheridan, C. (2016) · Nature Biotechnology · doi:10.1038/nbt0816-791 · Cited by 2
Cited by
Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer
Arjomandnejad, M., Dasgupta, I., Flotte, T. R., & Keeler, A. M. (2023) · BioDrugs · doi:10.1007/s40259-023-00585-7 · Cited by 159
“history of immune response to protein replacement therapy or null mutations were excluded from these studies [127, 128].”
BackgroundAfter Glybera's withdrawal, what's next for gene therapy?
Senior, M. (2017) · Nature Biotechnology · doi:10.1038/nbt0617-491 · Cited by 116
Baruteau, J., Waddington, S. N., Alexander, I. E., & Gissen, P. (2017) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-017-0053-3 · Cited by 110
“A lentiviral vector is currently in preclinical development for haemophilia B (Dolgin 2016).”
BackgroundMethodNienhuis, A. W., Nathwani, A. C., & Davidoff, A. M. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.033 · Cited by 99
“Data presented thus far show that the low dose (5 10(11) vg/kg) of their vector resulted in sustained FIX activity levels between 12% and 63% of normal following a single administration of SPK-9001 at the initial dose level studied in the trial.(29,31)”
BackgroundKondratov, O., Marsic, D., Crosson, S. M., Mendez-Gomez, H. R., Moskalenko, O., Mietzsch, M., Heilbronn, R., Allison, J. R., Green, K. B., Agbandje-McKenna, M., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.08.003 · Cited by 92
Metadata
- Authors
- Dolgin, E.
- Corresponding author
- Dolgin, Elie
- Venue
- Nature Biotechnology
- Published
- 2016-10
- Volume
- 34
- Issue
- 10
- Pages
- 999-1001
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2531523825
- Cited by
- 16
- References
- 5
- Citations by year
- 2023: 2 · 2022: 1 · 2021: 1 · 2020: 1 · 2018: 2 · 2017: 9
- Type
- other
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- hemophilia, gene therapy, factor VIII, factor IX, adeno-associated virus vectors, AAV capsid engineering, liver-directed gene transfer, clinical trials
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Early clinical data raise the bar for hemophilia gene therapies. https://app.cochat.ai/papers/10.1038/nbt1016-999
- The paper
- Dolgin, E. (2016). Early clinical data raise the bar for hemophilia gene therapies. Nature Biotechnology. https://doi.org/10.1038/nbt1016-999
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.